๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods

โœ Scribed by Gunnar Martensson; Anders Thylen; Ulla Lindqvist; Anders Hjerpe


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
447 KB
Volume
73
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Background:

Hyaluronan may be used as a marker for malignant mesothelioma, thus indicating its mesodermal origin.

Methods:

The sensitivity as a diagnostic test of three different methods for hyaluronan analyses of pleural fluid was examined in patients with biopsy-verified malignant pleural mesothelioma.

Results:

A quantitative high-performance liquid-chromatography (hplc) method was performed on fluids from 43 patients. using a cutoff level of 100 mg/l, higher levels were noted in 30 (70%) patients, with a median value of 220 mg/l (mean, 560 mg/l; range, 20-6600 mg/l). an identical median value (220 mg/l) was obtained with a radioassay method when simultaneously performed on paired samples from 21 patients (correlation coefficient, 0.91). a qualitative precipitation test using 0.5% cetylpyridinium chloride combined with a quantitative viscosimetric method was significantly less sensitive (p < 0.01).

Conclusion:

Hyaluronan analyses is beneficial in distinguishing malignant mesothelioma if methods such as the evaluated hplc or radioassay with a sensitivity of 70% toward mesothelioma are used and other known causes of elevated content are considered.


๐Ÿ“œ SIMILAR VOLUMES


Intrapleural administration of interleuk
โœ Philippe Astoul; Diane Picat-Joossen; Jean-Regis Viallat; Christian Boutin ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 82 KB ๐Ÿ‘ 2 views

## Background: The prognosis associated with malignant pleural mesothelioma (mpm) is poor in spite of surgery, radiotherapy, photodynamic therapy, or chemotherapy. therefore, new therapeutic strategies, including intrapleural immunotherapy, are being investigated. several clinical studies have demo

Intrapleural administration of interleuk
โœ Theodore G. Karrison; Nicholas J. Vogelzang ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 52 KB ๐Ÿ‘ 2 views

## Stage I Renal Cell Carcinoma I read the report by Kinouchi et al., 1 in which they concluded that the tumor grading of renal cell carcinoma was not predictive of the survival of Robson Stage I patients. This does not mean that the three-grading system is worthless; the authors simply showed tha

Cisplatin in combination with irinotecan
โœ Takashi Nakano; A. Philippe Chahinian; Miho Shinjo; Naoki Togawa; Atsushi Tonomu ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 161 KB ๐Ÿ‘ 2 views

The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci